ALKS - Alkermes plc.

29.28
0.080   0.273%

Share volume: 1,753,106
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$29.20
0.08
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
54%
Profitability 59%
Dept financing 33%
Liquidity 75%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.21%
1 Month
-12.73%
3 Months
-0.81%
6 Months
-2.20%
1 Year
-17.01%
2 Year
-1.61%
Key data
Stock price
$29.28
P/E Ratio 
19.13
DAY RANGE
$28.86 - $29.52
EPS 
$1.47
52 WEEK RANGE
$25.16 - $36.32
52 WEEK CHANGE
-$15.50
MARKET CAP 
4.620 B
YIELD 
N/A
SHARES OUTSTANDING 
166.650 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-23-2025
BETA 
1.24
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,484,383
AVERAGE 30 VOLUME 
$1,908,896
Company detail
CEO: Richard F. Pops
Region: US
Website: alkermes.com
Employees: 2,280
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alkermes plc researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL, and VUMERITY. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate.

Recent news